Summary of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings on Apr 16, 2018

April 16, 2018 - By Loretta Love

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Ratings Coverage

In total 2 analysts cover China Biologic (NASDAQ:CBPO). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 2 are the (NASDAQ:CBPO)’s analyst reports since March 2, 2018 according to StockzIntelligence Inc. In Thursday, March 15 report Jefferies maintained the stock with “Buy” rating. Listed here are China Biologic Products Holdings, Inc. (NASDAQ:CBPO) PTs and latest ratings.

15/03/2018 Broker: Jefferies Rating: Buy New Target: $97.0 Maintain
02/03/2018 Broker: Deutsche Bank Rating: Buy New Target: $105.0

The stock increased 0.51% or $0.44 during the last trading session, reaching $86.28.China Biologic Products Holdings, Inc. has volume of 131,541 shares. Since April 16, 2017 CBPO has declined 18.54% and is downtrending. CBPO underperformed by 30.09% the S&P 500.

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma biopharmaceutical products to hospitals and inoculation centers in the PeopleÂ’s Republic of China.The firm is valued at $2.86 billion. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.The P/E ratio is 36.25. The firm also provides human immunoglobulin and immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus.

China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: